Aromatase Inhibitor-Associated Bone Fractures: A Case-Cohort GWAS and Functional Genomics
Authors:
Open Access
- 1 October 2014
- journal article
- research article
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 28 (10) , 1740-1751
Abstract
Bone fractures are a major consequence of osteoporosis. There is a direct relationship between serum estrogen concentrations and osteoporosis risk. Aromatase inhibitors (AIs) greatly decrease serum estrogen levels in postmenopausal women, and increased incidence of fractures is a side effect of AI therapy. We performed a discovery case-cohort genome-wide association study (GWAS) using samples from 1071 patients, 231 cases and 840 controls, enrolled in the MA.27 breast cancer AI trial to identify genetic factors involved in AI-related fractures, followed by functional genomic validation. Association analyses identified 20 GWAS single nucleotide polymorphism (SNP) signals with P < 5E-06. After removal of signals in gene deserts and those composed entirely of imputed SNPs, we applied a functional validation “decision cascade” that resulted in validation of the CTSZ-SLMO2-ATP5E, TRAM2-TMEM14A, and MAP4K4 genes. These genes all displayed estradiol (E2)-dependent induction in human fetal osteoblasts transfected with estrogen receptor-α, and their knockdown altered the expression of known osteoporosis-related genes. These same genes also displayed SNP-dependent variation in E2 induction that paralleled the SNP-dependent induction of known osteoporosis genes, such as osteoprotegerin. In summary, our case-cohort GWAS identified SNPs in or near CTSZ-SLMO2-ATP5E, TRAM2-TMEM14A, and MAP4K4 that were associated with risk for bone fracture in estrogen receptor-positive breast cancer patients treated with AIs. These genes displayed E2-dependent induction, their knockdown altered the expression of genes related to osteoporosis, and they displayed SNP genotype-dependent variation in E2 induction. These observations may lead to the identification of novel mechanisms associated with fracture risk in postmenopausal women treated with AIs.Keywords
This publication has 39 references indexed in Scilit:
- Identification of Map4k4 as a Novel Suppressor of Skeletal Muscle DifferentiationMolecular and Cellular Biology, 2013
- Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fractureNature Genetics, 2012
- Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expressionBreast Cancer Research, 2012
- Genomics and Drug ResponseNew England Journal of Medicine, 2011
- Radiation pharmacogenomics: A genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell linesGenome Research, 2010
- FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating AktCancer Cell, 2009
- Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trialAnnals of Oncology, 2009
- Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer CellsCancer Research, 2008
- Biology of RANK, RANKL, and osteoprotegerinArthritis Research & Therapy, 2007
- Principal components analysis corrects for stratification in genome-wide association studiesNature Genetics, 2006